All In Biotech

Drug Trial Radar · NCT03244384

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 739 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

739

Planned (sponsor's estimate)

Start

Nov 3, 2017

Primary completion

Jan 1, 2027

Study completion Jan 1, 2027

Sponsor

Sponsor type
NIH
First posted
Aug 9, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial studies how well pembrolizumab works in treating patients with bladder cancer that has spread into the deep muscle of the bladder wall (muscle-invasive) or urothelial cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced). Monoclonal antibodies recognizing and blocking checkpoint molecules can enhance the patient's immune response and therefore help fight cancer. Pembrolizumab is one of the monoclonal antibodies that block the PD-1 axis and can interfere with the ability of tumor cells to grow.

Conditions

  • Localized Renal Pelvis and Ureter Urothelial Carcinoma
  • Locally Advanced Bladder Urothelial Carcinoma
  • Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma
  • Locally Advanced Ureter Urothelial Carcinoma
  • Locally Advanced Urothelial Carcinoma
  • Stage II Bladder Urothelial Carcinoma AJCC v6 and v7
  • Stage II Renal Pelvis and Ureter Cancer AJCC v7
  • Stage II Ureter Cancer AJCC v7
  • Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
  • Stage III Renal Pelvis and Ureter Cancer AJCC v7
  • Stage III Ureter Cancer AJCC v7

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Clinical ObservationOther

    Undergo observation

  • Computed TomographyProcedure

    Undergo a CT scan

  • CT UrographyProcedure

    Undergo a CT urography

  • CystoscopyProcedure

    Undergo a cystoscopy

  • Magnetic Resonance ImagingProcedure

    Undergo a MRI

  • PembrolizumabBiological

    Given IV

  • Pharmacological StudyOther

    Correlative studies

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • Questionnaire AdministrationOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: From randomization to the date of death from any cause, assessed up to 5 years
  2. Disease-free survivalTime frame: From randomization to the first metastatic recurrence (presence of any recurrent disease), or death, whichever occurs first, assessed up to 5 years

Locations

914 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • CTCA at Western Regional Medical Center

    Goodyear, Arizona

  • Kingman Regional Medical Center

    Kingman, Arizona

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona

  • Mayo Clinic in Arizona

    Scottsdale, Arizona

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas

  • John L McClellan Memorial Veterans Hospital

    Little Rock, Arkansas

  • Kaiser Permanente-Anaheim

    Anaheim, California

  • Mission Hope Medical Oncology - Arroyo Grande

    Arroyo Grande, California

  • PCR Oncology

    Arroyo Grande, California

  • AIS Cancer Center at San Joaquin Community Hospital

    Bakersfield, California

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California

  • Kaiser Permanente-Bellflower

    Bellflower, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Epic Care-Dublin

    Dublin, California

  • Bay Area Breast Surgeons Inc

    Emeryville, California

  • Epic Care Partners in Cancer Care

    Emeryville, California

  • Kaiser Permanente-Fontana

    Fontana, California

  • Kaiser Permanente South Bay

    Harbor City, California

  • Kaiser Permanente-Irvine

    Irvine, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Loma Linda University Medical Center

    Loma Linda, California

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California

  • Los Angeles General Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • Kaiser Permanente West Los Angeles

    Los Angeles, California

  • Contra Costa Regional Medical Center

    Martinez, California

  • Fremont - Rideout Cancer Center

    Marysville, California

  • Community Hospital of Monterey Peninsula

    Monterey, California

Showing 40 of 914 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.